The Counterintuitive Fix for Low Oxygen in Flight

Commercial aircraft cabins are not pressurised to sea level. Regulators allow the air inside to thin to the equivalent of a moderate mountain altitude, a compromise between structural engineering and passenger comfort that has stood largely unchallenged for decades. A study published in 2026 by researchers at the German Aerospace Center’s Institute of Aerospace Medicine in Cologne tested a genuinely counterintuitive fix for the low blood oxygen that results, adding carbon dioxide back into the air rather than trying to remove it.

A Six Hour Chamber Test at Cabin Altitude

The study, led by Titiaan Post and Daniel Aeschbach alongside colleagues including Jens Jordan, director of the DLR Institute of Aerospace Medicine, and published in the Journal of Applied Physiology in 2026, put 17 healthy adults, eight of them women, aged between 18 and 40, through a randomised double-blind crossover trial in a hypobaric chamber. Each participant spent six hours at a simulated pressure of around 565 millimetres of mercury, equivalent to roughly 2,438 metres or 8,000 feet, the same cabin altitude regulators permit on a real flight, once with ambient air containing a background 0.1 per cent carbon dioxide and once with the air enriched to 1.0 per cent carbon dioxide, with blood gases, tissue oxygenation and cognitive performance measured throughout.

The results were substantial for what amounts to a single percentage point change in gas composition. The proportion of time participants spent with blood oxygen saturation below 90 per cent fell from 18.8 per cent of the six hour exposure under normal cabin air to just 2.5 per cent with the carbon dioxide enriched air. Arterial oxygen tension rose from an average of 60.9 to 68.3 millimetres of mercury, and near infrared spectroscopy measurements showed brain tissue oxygenation increased from 62.8 to 63.9 per cent, though muscle tissue oxygenation showed no comparable change. Minute ventilation, the total volume of air breathed per minute, rose modestly from 9.7 to 10.4 litres, and cognitive performance on tests of attention, memory and coordination was unaffected either way.

Why Adding a Waste Gas Helps

The logic runs against the instinct that carbon dioxide is simply something the body needs to expel. In practice, a rise in ambient carbon dioxide is one of the strongest natural triggers for breathing itself, stimulating the chemoreceptors that drive ventilation rate more powerfully than a fall in oxygen does on its own. A person breathing slightly more, in response to slightly more carbon dioxide in the air, draws in more of the already thin oxygen available at altitude with each breath, which is reflected in the modest rise in minute ventilation the DLR team recorded alongside the improved blood oxygen figures. The authors’ own conclusion, stated directly in the paper, is that enrichment of cabin air with carbon dioxide during hypobaric hypoxia may improve blood and brain oxygenation, a mechanism distinct from the more familiar options of raising cabin pressure itself or supplying supplemental oxygen directly.

Set Against What Cabin Air Already Allows

The altitude the DLR team chose to test was not arbitrary. UK Civil Aviation Authority guidance for health professionals states that cabin altitude in commercial aircraft should not exceed 8,000 feet in normal operations, with cruising cabins typically sitting somewhat lower, between 5,000 and 7,500 feet. At the regulatory ceiling, the same guidance notes, arterial oxygen saturation in a healthy traveller falls to around 90 per cent, a level it describes as well tolerated, while flagging that passengers with respiratory disease, cardiac conditions or severe anaemia may not tolerate the reduction in barometric pressure as comfortably. The DLR study’s finding that even healthy young adults spent close to a fifth of a six hour exposure below that same 90 per cent threshold under ordinary cabin air conditions puts a number on what “well tolerated” actually looks like moment to moment, rather than as an average, and suggests there is meaningful room to improve on it without the far larger engineering cost of raising cabin pressure across an entire aircraft.

An Early Result, Not Yet a Redesign

The researchers describe their own work as a feasibility study, and the label is an accurate one. Seventeen healthy adults in a ground based chamber is a proof of concept rather than evidence ready for cabin design, and the participants were younger and fitter than the full range of passengers an aircraft actually carries, precisely the older and less healthy travellers the CAA’s own guidance flags as most vulnerable to reduced cabin pressure in the first place. Whether raising ambient carbon dioxide is practical, safe or even desirable across an aircraft full of several hundred people, rather than a small group in a research chamber, remains untested. What the study does establish is that a widely tolerated and long unquestioned feature of commercial flight, the amount of oxygen available to a passenger at cruising altitude, has more room for improvement than the current regulatory ceiling suggests, and that the fix need not come from the two options aviation medicine has traditionally reached for, more cabin pressure or bottled oxygen.

Sources: Journal of Applied Physiology (Post, Aeschbach et al, 2026); German Aerospace Center (DLR) Institute of Aerospace Medicine; UK Civil Aviation Authority (Physiology of Flight guidance for health professionals).

Author

Leave A Comment

Graham Combe

Strategic Consultant,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Graham Combe is an experienced strategic consultant, relationship builder, and entrepreneur in the global life sciences sector. He holds a BSc (Hons) in Chemistry from University College London (UCL) and spent over a decade with Nature, where he pioneered key initiatives such as Nature’s BioPharma Dealmakers and Nature’s SciCafe.

In May 2011, he founded Biosell UK, a consulting and event management firm that collaborates with global life science publishers, event organizations, and marketing partners. Beyond BioSell, Combe is the founder or co-founder of several prominent networking and thought-leadership platforms, including #BiotechBuddies, #coffeebuddies, the #AgileLeaders Forum, and the Creative Disruption Forum—the latter three events co-hosted with his business partner, Professor Tony Sedgwick.

Specializing in the early-to-mid stages of drug development (from pre-clinical research through Phase 3 and clinical proof-of-concept), Graham focuses on facilitating forums to promote peer-to-peer discussion, strategic growth, investment and meaningful connections between biotech innovators, investors, and industry service providers.

Apply for a complimentary Conference Day VIP Pass

Apply for a complimentary Conference Day VIP Pass

Complimentary Conference Day VIP Passes are reserved for senior leaders and decision-makers with influence over purchasing, commissioning, investment or technology advancements and adoption across UK life sciences.

A Conference Day VIP Pass includes:

  • Complimentary access-all-areas to the Launch Day Conference
  • Access to the dedicated VIP green room alongside Conference speakers
  • Access to all general keynote, panel and programme sessions
  • Curated networking opportunities
  • Opportunities to meet conference speakers and other approved VIP attendees

The VIP Pass applies to the Launch Day Conference only. It does not include admission to the Life Sciences Week Gala Dinner or other separately ticketed events.

Applications are reviewed individually and submitting this form does not guarantee a complimentary pass. To maintain a balanced, high-quality audience, we may limit the number of VIP Passes issued to any one organisation.

    First Name *

    Last Name *

    Work Email Address *

    Telephone Number *

    Job Title *

    Organisation *

    LinkedIn

    Organisation Information

    Which best describes your organisation? *


    If other, please specify

    Which best describes your level of seniority? *

    If other, please specify

    Which areas are you responsible for or directly involved in? *

    If other, please specify

    What best describes your role in purchasing, investment, commissioning or adoption decisions? *

    Attendance Information

    Briefly, what is the number one thing you are hoping to get out of attending Life Sciences Week 2026? *

    Final Confirmation

    Is your role primarily focused on selling products or services, consultancy, account management or business development? *

    Please Confirm *

    I understand that VIP applications are subject to review and approval.
    I understand that the complimentary VIP Pass covers the Life Sciences Week Launch Day Conference only and does not include the Gala Dinner Awards or other separately ticketed events.
    The information supplied in this application is accurate.

    Shabna Raja

    Advisory Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

    She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
    initiatives across commercial, data and operating model domains within regulated environments.

    Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

    More recently, she has spent over three years working closely with Haleon through a strategic
    services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

    Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

    Amjad Khan

    Executive Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

    Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt and scale emerging  technologies to drive meaningful outcomes.

    Dr. Richard Fallon | Business Consultant | WM Life Sciences

    Dr. Richard Fallon

    Co Founder, Life Sciences Week 
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

    As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

    Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

    With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

    Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

    Amy Deakin | Chief of Staff | WM Life Sciences

    Amy Deakin

    Event Managing Director,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

    Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

    Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

    An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

      Award Category Voting

      Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

      Day you've not voted in, will be denoted with an ❌

      If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

      Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

      Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

      No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

      Awarding an individual or organisation for exceptional long-term impact on the industry.

      No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

      Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

      No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

      Your Details